Experienced in Tongue Cancer

Dr. Megan E. Daly

Radiology | Radiation Oncology
3850 G St, 
Merced, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Tongue Cancer
3850 G St, 
Merced, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Megan Daly is a Radiologist and a Radiation Oncologist in Merced, California. Dr. Daly is rated as an Experienced provider by MediFind in the treatment of Tongue Cancer. Her top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Gastrostomy, and Microvascular Decompression.

Her clinical research consists of co-authoring 118 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Tongue Cancer.

Graduate Institution
Stanford University, School Of Medicine
Residency
Stanford Hospitals & Clinics
Specialties
Radiology
Radiation Oncology
Licenses
Radiology in CA
Board Certifications
Radiology Radiation Oncology
Hospital Affiliations
University Of California Davis Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Megan E. Daly, MD Private Practice
3850 G St, Merced, CA 95340

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Procedure, Radiation
Study Phase: Phase 3
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: November 25, 2025
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Drug, Procedure, Radiation
Study Drug: Atezolizumab
Study Phase: Phase 3
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Enrollment Status: Active_not_recruiting
Publish Date: November 14, 2025
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Paclitaxel, Veliparib
Study Phase: Phase 1/Phase 2
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.
Enrollment Status: Completed
Publish Date: October 18, 2022
Intervention Type: Radiation, Drug
Study Phase: Phase 1
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Radiation
Study Phase: Phase 1
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer
Enrollment Status: Completed
Publish Date: October 28, 2020
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Terminated
Publish Date: August 05, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 9 Less Clinical Trials

118 Total Publications

Real-World Clinical Outcomes and Biopsy Patterns of Older Patients with Unresected Non-Small-Cell Lung Cancer Treated with Primary Stereotactic Body Radiotherapy.
Real-World Clinical Outcomes and Biopsy Patterns of Older Patients with Unresected Non-Small-Cell Lung Cancer Treated with Primary Stereotactic Body Radiotherapy.
Journal: Journal of clinical medicine
Published: October 30, 2025
Similar Doctors
Advanced in Tongue Cancer
Dr. Nhat-long L. Pham
Radiation Oncology
Advanced in Tongue Cancer
Dr. Nhat-long L. Pham
Radiation Oncology

Community Health Partners

45 E River Park Pl W, Suite 507, 
Fresno, CA 
 (50.0 miles away)
Languages Spoken:
English, Vietnamese
See accepted insurances
Offers Telehealth

Nhat-long Pham is a Radiation Oncologist in Fresno, California. Dr. Pham is rated as an Advanced provider by MediFind in the treatment of Tongue Cancer. His top areas of expertise are Tongue Cancer, Throat Cancer, Laryngeal Cancer, Pleuropulmonary Blastoma, and Gastrostomy.

Experienced in Tongue Cancer
Dr. Christine N. Chang-Halpenny
Radiation Oncology
Experienced in Tongue Cancer
Dr. Christine N. Chang-Halpenny
Radiation Oncology

California Cancer Associates For Research And Excellence Inc

7130 N Millbrook Ave, 
Fresno, CA 
 (52.0 miles away)
559-326-1222
Languages Spoken:
English
See accepted insurances

Christine Chang-Halpenny is a Radiation Oncologist in Fresno, California. Dr. Chang-Halpenny is rated as an Advanced provider by MediFind in the treatment of Tongue Cancer. Her top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Pleuropulmonary Blastoma, and Muscle Invasive Bladder Cancer.

Experienced in Tongue Cancer
Dr. Mihoko Fujita
Radiation Oncology
Experienced in Tongue Cancer
Dr. Mihoko Fujita
Radiation Oncology

Parminder S Sidhu Medical Corporation

3850 G St, 
Merced, CA 
 (0.1 miles away)
209-564-3600
Languages Spoken:
English
See accepted insurances

Mihoko Fujita is a Radiation Oncologist in Merced, California. Dr. Fujita is rated as an Advanced provider by MediFind in the treatment of Tongue Cancer. Her top areas of expertise are Laryngeal Cancer, Throat Cancer, Intraductal Papilloma, and Familial Prostate Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daly's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 43 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile